Clinical trial
Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-015 in Patients With Retinitis Pigmentosa or Choroideremia (ENVISION)
NCT06460844 is registered in ClinicalTrials.gov with Ray Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-015 in Patients With Retinitis Pigmentosa or Choroideremia (ENVISION)
- Lead sponsor
- Ray Therapeutics, Inc.
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- August 27, 2024
- Completion date
- October 31, 2030
- Enrollment
- 10 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.